Double-Drug attack: new combo targets tough lung cancer
NCT ID NCT03122717
First seen Nov 12, 2025 · Last updated Jun 20, 2026 · Updated 31 times
Summary
This study tests whether combining two targeted drugs, osimertinib and gefitinib, is safe and feasible for people with advanced EGFR-mutant non-small cell lung cancer who have not taken similar drugs before. About 48 participants will receive the combination for up to 6 months. Researchers will track how many complete the full course, side effects, and whether tumors shrink.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
osimertinib (Tagrisso) and gefitinib (Iressa)
What this could lead to
If successful, this combination could offer a more effective treatment option for people with advanced EGFR-mutant lung cancer, potentially improving tumor shrinkage and delaying progression.
What could go wrong
This is an early-phase trial with only 48 participants, so results may not apply broadly. Combining two targeted drugs may increase side effects, and it is unclear if the combination is better than standard single-drug therapy.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.